

12th August, 2019

The Dy. General Manager (Listing Dept.)
BSE Limited
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: USFDA classifies inspection at Indrad facility as OAI

The Company has received a communication from the USFDA classifying the inspection conducted at its Indrad facility in April, 2019 as Official Action Initiated (OAI).

The Company already had submitted its initial response to USFDA and commitments given in response to Form 483 observations have been fulfilled. The Company is sending further updates over receiving of this OAI letter. The Company will be engaging with the regulator and is fully committed in resolving this issue at the earliest.


The Company does not believe that this inspection classification will have an impact of disruption of supplies or the revenues from operations of this facility.

This is for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY